Fractionated doses of oral etoposide in the treatment of patients with AIDS-related Kaposi sarcoma. A clinical and pharmacologic study to improve therapeutic index

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 2, 2001, Pages 177-184

  Sprinz, Eduardo ^a,b,c   Caldas, Ana P F ^a,b,c   Mans, Denis R ^a,b,c   Cancela, Anna ^a,b,c   DiLeone, Luciane ^a,b,c   Dalla Costa, Teresa ^a,b,c   Schwartsmann, Gilberto ^a,b,c,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b South American Office for Anticancer Drug Development SOAD   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

AIDS; Etoposide; Kaposi sarcoma; Pharmacokinetics; Phase II

Indexed keywords

ETOPOSIDE;

ADULT; AIDS RELATED COMPLEX; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMED CONSENT; KAPOSI SARCOMA; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTE COUNT; MALE; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; THRUSH; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; SARCOMA, KAPOSI;

EID: 0035058604     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200104000-00016     Document Type: Article

References (43)

1. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study
2. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-infected individuals. Multicenter AIDS Cohort Study
3. Epidemic (AIDS-related) Kaposi's sarcoma: Epidemiology, pathogenesis and treatment
4. Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment
5. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches
6. The systemic treatment of AIDS-related Kaposi's sarcoma
7. Treatment update for AIDS-related Kaposi's sarcoma
8. Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma
9. Recombinant alpha-2 interferon for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
10. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma
11. Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma
12. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma
13. Treatment of HIV- associated Kaposi's sarcoma with paclitaxel
14. Phase II trial dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma
15. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma
16. Preliminary results of IM-862 nasal solution in the treatment of patients with AIDS-related Kaposi's sarcoma
17. Phase I/II study of intermittent all trans retinoic acid alone and in combination with interferon alpha-2a in patients with epidemic Kaposi's sarcoma
18. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin
19. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial
20. Chronic daily administration of oral etoposide in refractory lymphoma
21. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy
22. Low-dose oral etoposide: A new role for an old drug?
23. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma
24. Clinical and pharmacologic analysis of hyperfractional daily oral etoposide
25. Phase I study of three-times daily oral etoposide in patients with refractory solid tumors
26. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide
27. Kaposi's sarcoma: A new classification
28. EORTC New Drug Development Office coordinating and monitoring program for phase I and II thais with new anticancer agents
29. Practical treatment guide for dose individualization in cancer chemotherapy
30. Etoposide for epidemic Kaposi's sarcoma: A phase II study
31. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: Therapeutic and pharmacoeconomic perspectives
32. A phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma
33. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
34. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/adolescent spectrum of HIV Disease Project Group
35. Complete histological regression of Kaposi's sarcoma following treatment with protease inhibitors despite persistence of HHV-8 in lesions
36. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: A prospective pilot study
37. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma
38. Bioavailability and pharmacokinetics of VP-16
39. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
40. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes
41. Population pharmacokinetics of total and unbound etoposide
42. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule